Frontlight ResearchEarly access
CompletedPhase 2
A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)
Key facts
- Who runs it
- Brii Biosciences Limited
- Where
- Atlanta, Boynton Beach, Davie, Decatur, Denver, Fort Worth, League City, Miami Springs, Sherman Oaks, and Torrance, United StatesSee the 11 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 11 people enrolled
- Started
- 29 Sept 2023
- Ended
- 13 Mar 2024
- Type of study
- Interventional
- Treatments tested
- BRII-296
- Depo Medrol
- Record updated
- 27 January 2025
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Participant either must have ceased lactating at screening or is still lactating actively breastfeeding at screening , must agree temporarily cease giving breast milk to her infant(s)
- Participant has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
- Participant was <12 months postpartum
- Participant is amenable to intramuscular administration of investigational product on Day 1 and remaining inpatient until at least Day 4
Who cannot take part
- Medical history of seizures
- Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder
- Active psychosis
- Attempted suicide associated with current episode of postpartum depression
Where in United States
- CenExel ACMR Atlanta Center for Medical ResearchAtlanta, United States
- Synexus Clinical Research US IncAtlanta, United States
- Clinical Research Center of FloridaBoynton Beach, United States
- Aventura Clinical Research, LLCDavie, United States
- iResearch Atlanta, LLCDecatur, United States
- Research Carolina EliteDenver, United States
- North Texas Clinical TrialsFort Worth, United States
- Maximos Ob/GynLeague City, United States
- South Florida Research Phase I-IV INCMiami Springs, United States
- Cenexel CNRSherman Oaks, United States
- Cenexel Cns - TorranceTorrance, United States
About the trial
What the trial wants to find out
The primary purpose of this study is to evaluate the safety and tolerability of BRII-296 administered by 2 intramuscular injections, administered with Depo Medrol as assessed by the incidence of adverse events, changes from baseline in vital signs, pulse oximetry, clinical laboratory evaluations, electrocardiograms (ECGs), Stanford Sleepiness Scale (SSS), Glasgow Coma Scale (GCS) in conjunction with clinical assessment, and suicidal ideation using the Columbia Suicide Severity Rating Scale (C-SSRS).
The group in the trial
- BRII-296 + Depo MedrolTreatment being tested
Participants will receive BRII-296 600 milligram (mg) and Depo Medrol (80 milligram per milliliter \[mg/mL\]) on Day 1 as a combination therapy.
Treatment: BRII-296 and Depo Medrol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Descriptive Efficacy of BRII-296 in Adults With Severe Postpartum Depression (PPD)
- Record updated
- 27 January 2025